Home › Core › ISCC-IDs › 28CrWtoKGw1AS

View ISCC-ID

Core Data

28CrWtoKGw1AS
ISCC-ID - digital asset identifier
CCLyh57WrorhK-CTAB58rqEMJSH-CDLAo4HK57Wne-CRAWk2NofN38u
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

antitumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9l brain tumor xenografts is preser

Ledger Reference

coblo
Source Ledger/Blockchain
626741
N-th ISCC Decleration on source ledger
29298a9d84a79dd15d8b5bbe54374f1f1b2b547ca6d48b639c3e684e73c72a08
Hash of block that includes the ISCC-DECLARATION
ba79442dd875ffd7a1db0c5449061134a0f83417cf7adf5e4201b342a2ebd056
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Joshua C Doloff", "@type": "Person"}, {"name": "Chong-Sheng Chen", "@type": "Person"}, {"name": "David J Waxman", "@type": "Person"}], "license": "cc-by", "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://molecular-cancer.biomedcentral.com/track/pdf/10.1186/1476-4598-13-158", "encodingFormat": "application/pdf"}], "publisher": {"name": "Springer Nature", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1186/1476-4598-13-158", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCLyh57WrorhK-CTAB58rqEMJSH-CDLAo4HK57Wne-CRAWk2NofN38u", "propertyID": "ISCC"}], "datePublished": "2014-01-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close